CAM
ENSC icon

Cresset Asset Management’s Ensysce Biosciences ENSC Stock Holding History

Cresset Asset Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$13K – 985
2022
Q1 		$13K Hold
3
– – ﹤0.01% 980
2021
Q4 		$53K Sell
3
-1
-25% -$9.42K ﹤0.01% 1106
2021
Q3 		$42K Buy
+4
New +$78.2K ﹤0.01% 1098

Other funds holding ENSC

HVCM
HG Vora Capital Management New York $191M AUM 1.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cresset Asset Management's ENSC Position: Q2 2022 in Review

Cresset Asset Management sold out of Ensysce Biosciences (ENSC) in Q2 2022, closing a stake of 3 shares — an estimated $13K sold.

Cresset Asset Management first reported a position in ENSC in Q3 2021 and held it in 3 quarters. The position peaked at $53K in Q4 2021. 16 funds tracked by Wall St. Rank hold ENSC as of Q2 2022.

  • Cresset Asset Management reported no remaining Ensysce Biosciences position as of Q2 2022 after selling out during the quarter.
  • Cresset Asset Management sold 3 Ensysce Biosciences shares in Q2 2022, an estimated $13K.
  • Cresset Asset Management first reported a position in Ensysce Biosciences in Q3 2021 and held it in 3 quarters.
  • Cresset Asset Management's Ensysce Biosciences position peaked at $53K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2022.

Based on Cresset Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.